Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Trulicity ® (dulaglutide)
Trulicity® (dulaglutide): Hypersensitivity Including Anaphylactic Reactions and Angioedema
Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with dulaglutide.
Dulaglutide is contraindicated in patients with a known hypersensitivity to dulaglutide or to any of the excipients.1
Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported in patients treated with dulaglutide and other glucagon-like peptide-1 receptor agonists. 2
If a hypersensitivity reaction occurs, discontinue dulaglutide, treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous hypersensitivity reaction to dulaglutide.2
Clinical Study Experience
In the phase II and phase III clinical studies, systemic hypersensitivity events (e.g., urticaria, oedema) were reported in 0.5 % of patients receiving dulaglutide.1
There have been reports of anaphylactic reactions and angioedema during postapproval use of dulaglutide.2
Reporting rates of anaphylactic reactions have been very rarely reported in patients receiving dulaglutide, <0.01%.2
GLP-1 RA = glucagon-like peptide-1 receptor agonist
Date of Last Review: April 06, 2020